CytoDyn Inc (OTCMKTS:CYDY) went into full beast mode last week after the Company became one of the first biotechs to have an effective drug in the global fight against coronavirus COVID-19 world epidemic.
The leronlimab story is just getting picked up by mainstream press over the weekend with many national publications printing stories on leronlimab on Saturday. If leronlimab continues to show this kind of promise CYDY is going to have an April for the record books.
CytoDyn Inc (OTCMKTS:CYDY) is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Leronlimab has been hailed as a possible wonder drug and has demonstrated significant potential to attack a number of diseases and is currently being evaluated for dozens of indications including many types of cancer as well as HIV.
Last week, under FDA approval using an emergency IND Leronlimab was tested on a number of patients with serious respiratory conditions with Covid-19 in NYC. The drug is said to mitigate the “cytokine storm” which makes respiratory congestion so dangerous. According to CytoDyn, filling the CCR5 receptor with a harmless monoclonal body will prevent further damage.
The story was being picked up by international media on Saturday both in Europe and the USA. According to the Daily Mail; Two coronavirus patients in New York City were treated with a new drug ‘fast-tracked’ for HIV and breast cancer – and they went from being on ventilators in the ICU to regular hospital in a matter of days. Based on the results of a small initial trial, biotech firm CytoDyn believes their drug, leronlimab, has potential for treating patients severely ill with coronavirus. They believe that the drug can quell the ‘cytokine storm’ – a deluge of immune cells that can be as damaging as the infection itself – that triggers life-threatening lung inflammation in coronavirus patients. The article noted: “Leronlimab has only been tested in seven critically ill patients thus far, but two are now free from ventilators, and another two more show signs that the severe inflammation sending their lungs into organ failure are subsiding.”
CytoDyn CEO Nader Pourhassan appeared in a youtube video with ProactiveInvestors. Pourhassan, together diagnostics company IncellDx’s, CEO Dr. Bruce Patterson says evaluation of test results from the first four patients show “immunological benefits within three days” following treatment with leronlimab on all four patients, and “lower level of cytokine storm, especially IL-6 and TNF-α, which were reduced significantly.”
To Find out the inside Scoop on CYDY Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
On Friday CytoDyn said, at the suggestion of the FDA, the Company filed another round of modifications to its IND and protocol for a Phase 2 clinical trial with leronlimab (PRO 140). In addition, the FDA suggested the Company file a second randomized protocol for all COVID-19 patients in severe condition, so as to preclude each physician from filing an emergency IND for every patient to be treated with leronlimab.
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, “On behalf of all COVID-19 patients, we are thankful for the FDA’s responsiveness and their ability to provide timely guidance in order to collaboratively finalize our Phase 2 trial protocols. We will now also immediately file a second trial protocol, per the FDA’s suggestion, for severely ill COVID-19 patients.”
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $643 million market valuation, CYDY is running up the charts after the Company became one of the first biotechs to have an effective drug in the global fight against coronavirus COVID-19 world epidemic. leronlimab which has been hailed as a poassible wonder drug has been found to have significant potential to attack a host of diseases besides just HIV and its benign safety profile sets it apart from other therapies. leronlimab treatment for coronavirus is targeted as a therapy for patients who experience respiratory complications. The drug is believed to provide therapeutic benefit to a large subgroup of covid patients with serious respitory distress by enhancing the immune response while mitigating the “cytokine storm” that leads to morbidity and mortality in these patients. The fact that main stream media is beginning to pick up the story with gusto over the weekend bodes well for current shareholders We will be updating on CYDY when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CYDY.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in CYDY either long or short and we have not been compensated for this article.